ICER Finds Insufficient Clinical Benefit for Controversial Alzheimer’s Drug in Revised Report and Calls for Price Reduction Ahead of CTAF meeting

The Institute for Clinical and Economic Review (ICER) has issued a revised evidence report on Biogen’s Aduhelm, or aducanumab. ICER notes that the drug’s clinical benefit remains unclear and that its price tag of $56,000 per year is well above its recommended benchmark price range. The report will be discussed on July 15^th at a California Technology Assessment Forum (CTAF) meeting.

“Despite substantial uncertainty regarding aducanumab’s health benefits, ICER’s base-case cost-effectiveness analysis combined the results from the two contradictory phase III randomized trials. ICER’s health-benefit price benchmark (HBPB) range for aducanumab is $3,000-$8,400 per year for patients with early Alzheimer’s disease.” Read more here.

(Source: ICER, 6/30/21)